FindTrial
Sign In

A study of the therapeutic role of baicalin on non-alcoholic steatohepatitis by down-regulating the expression of miR103/107 and its mechanisms

A study of the therapeutic role of baicalin on non-alcoholic steatohepatitis by down-regulating the expression of miR103/107 and its mechanisms

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16008014
Enrollment
Unknown
Registered
2016-02-27
Start date
2016-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic steatohepatitis

Interventions

control group:Placebo
baicalin group:baicalin
metformin group,:metformin
baicalin plus metformin group: baicalin plus metformin

Sponsors

the Central Hospital of Qingdao
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: non-alcoholic steatohepatitis with type 2 diabetes

Exclusion criteria

Exclusion criteria: Viral hepatitis, alcoholic hepatitis, autoimmune hepatitis and drug-induced hepatitis

Design outcomes

Primary

MeasureTime frame
Liver enzymes;miR-103/107;—

Countries

China

Contacts

Public ContactYAO Min-xiu
yaominxiu@medmail.com.cn+86 18660229280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026